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Contrast-enhanced computed tomography
in acute pancreatitis: does contrast medium
worsen its course due to impaired
microcirculation?
Abstract Background: An early and
accurate diagnosis of severe acute
(necrotizing) pancreatitis is important
to allow timely institution of therapy to
limit the extra-pancreatic sequelae of
this necrotizing process and to mini-
mize the incidence of super-infection
of the necrosis (i.e., progression to
infected necrosis). Contrast-enhanced
computed tomography (CECT) has
become the cornerstone of diagnosis
by confirming the clinical diagnosis of
severe acute pancreatitis based on the
various clinical scoring criteria.
Moreover, CECT serves as an
anatomic roadmap for guiding radio-
logical and surgical interventions.
However, still-controversial experi-
mental studies in animals in the
mid-1990s suggested that the use of
intravenous radiographic contrast
media early in the course of the disease
might exacerbate the necrotizing pro-
cess by further impairing the already
compromised pancreatic microcircu-
lation. A series of experimental and
clinical studies followed that have both
refuted and supported this claim;
unfortunately, none is conclusive, and
the topic remains, as yet, unresolved.
Aims: Our objective was to review
objectively the available literature
found by a Medline search on this
subject. Methods: Meta-analysis and
review. Results and conclusion: Our
conclusion, after analysis of these
studies, is that there are no well-
substantiated data that could resolve
the controversy. However, several
caveats will be offered.
Keywords Acute pancreatitis .
Computed tomography . Contrast
medium . Microcirculation
Introduction
Severe acute pancreatitis remains a devastating disease, the
hallmark of which is the presence of necrosis of the pan-
creatic parenchyma and/or the peripancreatic retroperito-
neal tissues. Early treatment within the initial hours of onset
of symptoms in an intensive care unit utilizing aggressive
hemodynamic resuscitation, nutritional support and, possi-
bly, prophylactic antibiotics have served to decrease mark-
edly the mortality over the past three decades [1–9]. The
advent of a more objective means of imaging the necrosis
(or more specifically imaging the lack of vascular perfu-
sion) has contributed to this success. Similarly, different
clinical and biochemical prognostic paradigms, such as C-
reactive protein, interleukins or procalcitonin, have been
developed, not only to predict future complications, but,
more importantly, to classify those patients at highest risk of
developing potential complications, so that an aggressive
therapeutic regimen can be instituted early in the course of
the disease [3, 4, 10–19].
J. A. Plock .J. Schmidt . A. Roggo (*)
Department of Surgery,
University Hospital of Bern,
Inselspital,
3010 Bern, Switzerland
e-mail: antoine.roggo@insel.ch
Tel.: +41-31-6322111
Fax: +41-31-6324757
J. Schmidt
Department of Surgery,
University Hospital of Bonn,
Bonn, Germany
S. E. Anderson
Department of Radiology,
University Hospital of Berne,
Berne, Switzerland
M. G. Sarr
Department of Surgery, Mayo Clinic,
Rochester, Minnesota, USA
Clinical assessment and classifications of acute pancreatitis
Acute pancreatitis is a complex, frequent, and potentially
life-threatening inflammatory disorder, which varies in spec-
trum from amild to a severe clinical presentation.While the
mild and moderate forms often have a self-limiting course,
with negligible mortality, complications in the severe,
fulminate form of this disease can occur, with development
of the systemic inflammatory response syndrome (SIRS),
pancreatic necrosis, infected necrosis, pancreatic abscess,
hemorrhage, colonic necrosis, and pancreatic pseudocyst
formation, many of which obligate a high mortality rate
[1, 20]. Infected necrosis and systemic sepsis with multi-
organ failure may ensue, carrying a very high morbidity
rate and a mortality rate of up to 40% [2, 5, 20–22].
Once the diagnosis of pancreatitis is suspected, the use
of one of three current clinical classification systems will
help to identify those patients at highest risk, i.e., that
subset of severe acute (necrotizing) pancreatitis [5–9, 16,
23, 24]. Computed tomography (CT) is the most readily
available and reliable imaging modality to assess suspected
pancreatic disease [1, 2, 16, 23–28]. Intravenous contrast-
enhanced computed tomography (CECT) is accepted as the
current gold standard for the verification and determination
of the degree of the disease in the assessment of severe
acute pancreatitis and for detecting and estimating the ex-
tent of pancreatic parenchymal necrosis [1, 16, 23–28].
Most surgeons and gastroenterologists seem to prefer the
clinical staging systems (Ranson, Glasgow, APACHE II)
for the initial assessment and reserve the CECT for patients
with severe acute pancreatitis in an attempt to identify
the presence of complications of the pancreatitis, such as
infected necrosis, abscess or pseudocysts [2, 3, 17–19,
29–31] (Fig. 1).
The presence of ≥3 Ranson [10] or Glasgow [11]
criteria or ≥8 points in the acute physiology and chronic
health evaluation II criteria (APACHE II) [12] reliably
identifies those patients with necrotizing pancreatitis with
a sensitivity approaching 85%. Although a small percent-
age of patients with documented necrotizing pancreatitis
will have few, if any, of the clinical parameters used in
these scoring systems [13, 14], the majority of patients with
severe acute pancreatitis should be able to be recognized
clinically, thereby allowing treatment to begin appropri-
ately early in the course of the disease.
In mild forms of acute pancreatitis, an interstitial, edem-
atous “pancreatitis” is present, characterized microscop-
ically by marked edema of the interstitial space, with a
minimal number of inflammatory cells present. Major ne-
crosis of the pancreatic parenchyma is notably absent, al-
though focal, microscopic acinar cell necrosis may arise
[15, 26, 32]. Severe acute pancreatitis is associated with
organ failure and/or local complications such as necro-
sis, abscess or pseudocysts. Intrapancreatic fat necrosis
and acute inflammation represent the histological find-
ings, in addition to confluent zones of acinar cell necrosis
[15, 26, 32].
Imaging modalities in necrotizing pancreatitis
Numerous diagnostic imaging modalities are potentially
available to detect the presence of acute pancreatitis, in-
cluding transabdominal (or endoscopic) ultrasonography,
endoscopic retrograde cholangiopancreatography (ERCP),
CT, and,more recently, magnetic resonance imaging (MRI).
While all are effective in recognizing the presence of pan-
creatitis, their ability to detect the presence of tissue ne-
crosis and the development of late complications of the
pancreatitis vary markedly [16, 28, 33–35]. Recognition of
the necrotizing component of severe acute pancreatitis (i.e.,
necrotizing pancreatitis) is very important for prognosis as
well as for guiding therapy. Over the past 20 years CT has
evolved as the most cost-effective and sensitive imaging
modality, not only for confirming the clinical diagnosis of
severe acute pancreatitis, but, more importantly, for pre-
dicting and staging the severity of the pancreatitis and for
detecting the presence of serious complications [1, 2, 16,
23, 24, 26, 35–38]. The introduction and development of
CECT permits recognition of viable (contrast-enhanced)
and non-viable (non-enhancing) pancreatic parenchyma
(Fig. 2).
CECT is optimally performed technically by taking
the CT cuts of the peripancreatic area at the peak of pan-
creatic arterial perfusion, using a sufficiently high volume
of iodinated contrast medium given as a rapid bolus infu-
sion [1, 16, 24, 26]. The reported sensitivity of CECT for
the detection of necrosis in acute pancreatitis is 85%–92%,
Fig. 1 CT scan with cystic (*) and necrotic alterations in patient
with severe acute pancreatitis (arrows determine the extension of the
pancreas)
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while the specificity of CECT has been shown to be 95%–
100% [29, 36, 37]. A positive correlation has been demon-
strated between the prognostic signs, CT findings, and the
clinical course. Balthazar and colleagues [23] classified the
severity of findings on CECT appearance into five cate-
gories—A to E. Patients with pancreatitis of grades A–C
usually manifest a mild, uncomplicated, clinical course,
whereas grades D and E have a more prolonged course,
with a higher morbidity rate, a higher incidence of pan-
creatic infection, and a higher mortality rate. According to
this classification, the presence of necrosis and an acute
inflammatory reaction are the two most important prog-
nostic factors in the assessment of severity of acute pan-
creatitis. Using these two prognostic factors, Balthazar
et al. [39] established a grading system (Table 1) called the
CT severity index (CTSI); patients with a CTSI of 0–3 had
morbidity and mortality rates of 8% and 3%, respectively,
while patients with a CTSI of 7–10 had rates of 92% and
17%, respectively. The high specificity and sensitivity of
CECT is, nevertheless, somewhat dependent on the time at
which it is performed, as the complications seen in CECT
and used for grading the severity of acute pancreatitis need
time to develop.
Contrast-enhanced computed tomography and
microcirculation in acute pancreatitis—the controversy
Marked reduction in the pancreatic microcirculation is an
important mechanism in the pathophysiology of acute nec-
rotizing pancreatitis, undoubtedly occurring in response to
a variety of toxic, biologically active compounds [tumor
necrosis factor-α (TNFα), interleukins, cytokines, etc.] re-
leased locally from the inflamed pancreas [40–47]. In a
series of experimental studies using a rat model of acute
pancreatitis [48–51], several investigators have provided
evidence to suggest that the intravenous contrast media
used for imaging of parenchymal enhancement in CECT
aggravates the impairment of the pancreatic microcircula-
tion during the early phases of acute pancreatitis. These
experimental studies have sparked an ongoing controversy
about the benefit or harm of CECT in the course of acute
pancreatitis in humans and whether or not CECT is even
necessary in the diagnosis of necrotizing pancreatitis in its
early phase of acute pancreatitis [1–4, 14, 16, 19, 23–27,
29–31, 35, 37–39]. We will discuss the available clinical
and experimental data on this topic chronologically.
Fig. 2 Axial magnetic reso-
nance image (T2) with diffusely
enlarged pancreas head (arrows)
in acute pancreatitis
Table 1 Calculation of CTSI [32]
Parameter Observation Index
a) Inflammatory process
Grade A Normal pancreas 0
Grade B Focal or diffuse enlargement of pancreas 1
Grade C Pancreatic gland abnormalities associated
with peripancreatic inflammation
2
Grade D Fluid collection in a single location 3
Grade E Two or more fluid collections and/or the
presence of gas in/or adjacent to pancreas
4
b) Gland necrosis
No necrosis 0
<30% necrosis 2
30–50% necrosis 4
>50% necrosis 6
CTSI a) + b) Maximum 10
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Animal models
In 1994, Foitzik et al. [48] studied an experimental model
of graded acute pancreatitis in rats induced by intravenous
cerulein followed by retrograde biliopancreatic ductal infu-
sion of saline (mild acute pancreatitis) or differing amounts
of glycodeoxycholic acid (moderate and severe acute pan-
creatitis). Animals with each severity of acute pancreatitis
were divided into three groups to receive either intravenous
0.9% saline, or non-ionic, or ionic radiographic contrast
material 7 h after initiation of acute pancreatitis. The ani-
mals were killed 24 h later, and the pancreata were ana-
lyzed microscopically. In one group receiving intravenous
contrast agent, 20 of 36 animals (56%) died during the first
24 h before the planned time for assessment. Because of the
unexpected early mortality in this subgroup, the authors
concluded that “the use of CECT to detect poorly perfused
areas in the pancreas early in the course of acute severe
pancreatitis may deserve to be reconsidered”.
Later in 1994 and using the same animal model [49],
those investigators further studied the topic by measuring
hemoglobin content and oxygen saturation in pancreatic
tissues in vivo, using diffuse reflectance spectrometry. The
oxygen saturation of hemoglobin was reduced markedly in
necrotizing pancreatitis in the rats given the intravenous
contrast agent, suggesting that the radiological contrast
agent impaired the pancreatic microcirculation in the nec-
rotizing form of acute pancreatitis and, thereby, that “use
of contrast-enhanced computed tomography early in human
acute pancreatitis may promote the evolution of pancreatic
necrosis”.
In 1995 the third study from that group investigated
pancreatic capillary blood flow, using intravital microsco-
py in the same rat model of acute necrotizing pancreatitis
[50]. That study showed a marked decrease in total capil-
lary blood flow in the pancreas in the group receiving the
intravenous contrast agent. In addition, pancreatic vaso-
motion was analyzed in high-flow areas containing pre-
dominantly edematous changes as well as in low-flow
areas with evolving necrosis. In the group receiving the
contrast agent, capillary flow decreased significantly in the
low-flow, but not in high-flow capillaries when compared
to control animals. Those observations suggested that
“radiographic contrast medium further impairs pancreatic
capillary blood flow primarily in areas with pre-existing
low-flow conditions and frequently converted poorly per-
fused regions to frank capillary stasis in experimental
necrotizing pancreatitis”.
That same year Hotz et al. [51] investigated the effect of
hemodilution with dextran 70 versus Ringer’s lactate on the
pancreatic microcirculation in low-flow areas in rats re-
ceiving an intravenous contrast agent during acute necro-
tizing pancreatitis. Complete capillary stasis was greater in
the capillaries of the Ringer’s lactate group than in the
dextran group (22±5% vs 2±1% of capillaries, P<0.002).
The investigators concluded that “while the mechanism of
impaired pancreatic microcirculation induced by contrast
medium is not yet clear, dextran seems to have a therapeutic
effect on the specific impairment of pancreatic microcircu-
lation during acute experimental pancreatitis”.
Those studies, all in the same rat model of severe acute
pancreatitis, suggested a potentially deleterious effect of
iodinated radiographic contrast medium given during the
early development of acute pancreatitis. In contrast, Kaiser
and co-workers [52], in 1995 and using a different experi-
mental model in the opossum, found contradictory re-
sults, complicating the issue. The group studied an opossum
model of necrotizing pancreatitis induced by surgical liga-
tion of the common bile/pancreatic duct. Beginning 48 h
and 96 h later, intravenous contrast medium was infused
into half the animals. When they were killed 3 days later,
their serum amylase activity, pancreatic edema, acinar ne-
crosis, and macroscopic/microscopic morphometric anal-
ysis of inflammation were similar in both groups. The
authors concluded that “the concept that administration of
contrast medium during early stages of pancreatitis is
dangerous should not be accepted until additional experi-
mental and clinical studies support its validity”.
In 1998, Werner et al. [53] investigated the use of intra-
venous gadolinium-diethylenetriamine penta-acetic acid
(GD-DTPA), an intravenous contrast agent used for MRI,
using the same experimental rat model of Schmidt et al.
[50]. They found no change in total capillary flow in the
pancreas in the rats given intravenous GD-DPTA, as well
as no changes in low-flow areas with evolving pancre-
atic necrosis compared to control rats given normal saline.
Based on their two experimental studies, the group con-
cluded that, in this rat model, use of GD-DPTA for MRI
was safe in the early diagnosis of acute necrotizing pan-
creatitis when compared with the impairment of micro-
circulatory events induced by the intravenous contrast agent
used in CT.
Can the results in animal models be transferred to
human acute pancreatitis?
Those experimental studies had several limitations, espe-
cially when directly translating their results to the human
scenario. First, in the study by Foitzik et al. [48], not all
the animals were examined for histological changes, nor
for the effects of the intravenous contrast agent. Similarly,
the cause of death, the measure of outcome in this study,
was not established nor reported. In addition, there was no
control group of animals for the assessment of intravenous
contrast agent alone. In the second study by Foitzik et al.
[49] the authors failed to describe how many animals were
examined, and they did not provide statistical justification
for any difference between the two groups of animals con-
cerning use of the intravenous control agent.
In human pancreatitis, acinar changes occur first, fol-
lowed by progression of the necrotizing process to involve
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the vascular, ductal, and pancreatic/peripancreatic fat. These
changes have been questioned by Balthazar and Freeny
[25] in the rat model, but Rau et al. [54] were also able to
demonstrate the early involvement of acinar cells in the
course of acute pancreatitis. Balthazar and Freeny [25]
also questioned the appropriateness of the timing of ad-
ministration of intravenous contrast agent. Foitzik et al.
[48, 49] infused the contrast agent 7 h after induction of
pancreatitis, while in humans, CECT for acute pancre-
atitis is rarely performed earlier than 24 h after onset of
the clinical symptoms. There were no data to support the
hypothesis that the rats died because of increased necrosis
after administration of intravenous contrast material. Nev-
ertheless, the studies were performed carefully and in detail,
with appropriate animal numbers, which enables a conclu-
sion to be drawn, at least in this rat model.
Others argue that the model of Kaiser et al. [52], ligation
of the common bile/pancreatic duct, more closely reflects
the human situation (at least for pancreatitis). In this model
there were no deleterious effects of intravenous contrast
material when given 48–96 h after induction of pancre-
atitis, a time more consistent with the timing of CECT used
in the clinical situation. However, we must acknowledge
the marked differences between the studies. While many
more animals have been studied with the use of the origi-
nal rat model of Foitzik et al. [48] versus that of the opos-
sum model of Kaiser et al. [52], it remains unknown which
model is most appropriate for humans. In addition, the time-
points of administration of contrast medium were different:
7 h after induction of acute pancreatitis in Foitzik’s study
and 48 h and 96 h in Kaiser’s study. Kaiser’s animals were
additionally pretreated with antibiotics for 1 week for pre-
vention of skin infection, with the last dose on the day of
operation, which was an attempt to reproduce prophylactic
antibiotics for severe acute pancreatitis. The conclusions
drawn from the multiple studies in the rat model were to
avoid early CECT in the course of severe acute pancreatitis,
if no contradictions exist. The study by Kaiser et al. [52] in
the opossum model found no adverse effects of intravenous
contrast medium, when given at somewhat later times after
onset of acute pancreatitis and, of course, in a different
animal model.
Results from clinical studies of early CECT
Inspired by the controversial findings in 1996,McMenamin
and Gates [55] reported a retrospective clinical analysis of
the effect of CECT on the course of 57 patients with acute
pancreatitis. The 31 patients who underwent CECT ap-
peared to have a longer duration of clinical acute pan-
creatitis than the 26 patients not undergoing CECT (11±2 vs
6±1 days, P=0.004), despite their having similar APACHE-
II scores at admission. This uncontrolled, retrospective
review suggested that the use of intravenous contrast dur-
ing CT might be deleterious. Another clinical study by
Carmona-Sanchez et al. in 2000 [56] reviewed the effect of
intravenous contrast agents on the course and outcome of
126 patients with clinically mild acute pancreatitis, 52
of whom underwent CECT. In the CECT group, six of 52
patients developed local or systemic complications com-
pared to only one of the 74 patients who did not undergo
CECT (P<0.02). In addition, median hospital stay was
longer (18.4 vs 11.4 days; P<0.01), leading these authors to
conclude, “Although other factors cannot be excluded, such
as severity not adequately identified, this association
(increased incidence of local and/or systemic complications
in the CECT group) suggests a potentially harmful effect of
intravenous contrast material.” The primary criticism of
those two retrospective studies revolve around their retro-
spective design and the question of comparability of the
groups compared. Obviously, one group was subjected to
CECT, while the other group was not, raising the question
of presumed severity of the pancreatitis in the CECT group
(Fig. 3).
In contrast, Hwang et al. [57] conducted a randomized,
prospective trial in 20 patients with severe acute pancre-
atitis, comparing outcome in patients undergoing CT with
or without intravenous contrast agent on the first day of
admission. No significant differences between groups were
detected in numerous laboratory parameters of pancreati-
tis, including serum amylase and lipase activities, nor in
concentrations of serum C-reactive protein, creatinine, and
calcium when evaluated at multiple time points during
hospitalization. Overall morbidity, duration of hospital stay,
and mortality also showed no significant differences. The
authors concluded, “these data may support us in allowing
patients with acute pancreatitis to undergo an abdominal
CT examination with enhancing contrast medium.” How-
ever, conclusions from that study are somewhat limited
compared to the other clinical studies, because the number
of patients included seemed to be small. Unfortunately, no
follow-up (CE)CT was performed.
In 2002 Uhl et al. [58] reported a retrospective, re-
analysis of 302 patients entered initially into a randomized,
double-blind, multicenter trial of the use of octreotide in
patients with moderate to severe acute pancreatitis; 264
patients underwent CECT after onset of symptoms, while
38 patients did not. In 189 patients, CECT was performed
during their hospital course. Octreotide proved to be of no
benefit. Although patients in the CECT group at admission
had more severe acute pancreatitis, as indicated by a higher
C-reactive protein and APACHE-II score than the patients
without CECT, the early (<14 days) mortality rate was less
(3.8% vs 15.8%, P<0.002) as was the 1-month mortality
rate (6.4% vs 15.8%, P<0.04). Systemic and local compli-
cations (shock, sepsis, fluid collections) occurred with
similar frequency in both groups. The authors concluded
that their findings “could contribute to change the clinical
practice in approaching patients with severe acute pancre-
atitis”. Any negative effects of the intravenous contrast
agent should have been detected, because CECT was per-
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formed within 96 h of the onset of clinical symptoms. No
deleterious effects on the clinical course or radiological
findings were detected secondary to the administration of
the intravenous contrast medium. Indeed, repetitive use of
CECT seemed to reduce mortality by increasing the de-
tection of potential complications requiring the need for,
and best timing of, surgical therapy. However, that study,
like those by McMenamin and Gates [55] and Carmona-
Sanchez and colleagues [56] is subject to the same criticism
of a retrospective analysis.
In 1999, Wang et al. [59] stated that, in their opinion,
there is an increased alteration of the microcirculation in
vivo after administration of intravenous radiographic con-
trast agent in acute pancreatitis and that this might con-
tribute to the progression of severity of pancreatitis. Those
authors suggested that low osmolar, non-ionic, radiograph-
ic contrast medium would be less vasoactive than ionic
contrast and, therefore, should be used preferentially in the
assessment of acute pancreatitis. This contention was not
supported by the findings of Foitzik et al. [48], which
suggested that non-ionic agents did not provide any benefit
over ionic contrast agents. In the microvascular system, the
radiographic agents primarily seem to cause vasodilatation,
with the exception of the kidney where they lead to vaso-
constriction [60, 61].
The last important studies of this topic utilized magnetic
resonance technology in acute pancreatitis. Hirota et al.
[33] reported that pancreatic necrosis could be imaged by
gadolinium-enhanced MRI as well as by CECT. In their
prospective study, MRI even proved superior to CECT in
differentiating regions of pancreatic necrosis from perine-
crotic fluid collections and in visualization of heterogene-
ity within the pancreatic necrosis. Similar findings were
reported by Zhang et al. in 2003 [34] and by Arvanitakis
et al. in 2004 [62]. Those authors also addressed impor-
tant logistic problems, e.g., the use of MRI in severely ill
patients in the intensive care unit, the higher costs of MRI
versus CT, and the availability of MRI scanners for emer-
gency and routine use in the community. An increasing
number of reports support a role for MRI in the diagnosis
and assessment of acute pancreatitis [63–67]. However, a
cautionary note is pertinent. Two case reports in the litera-
ture suggest that acute pancreatitis may occur after admin-
istration of gadodamide (Omniscan, Nycomed, Ireland).
The letter in Lancet 1999 by Terzi and Sokmen [68], and its
clarification by Tsushima and Endo in 2000 [69], as well as
the report in 2001 by Schenker et al. [70], are important,
because the current literature and specific studies of this
topic in both animals and humans are lacking. We could not
find any reports suggesting that gadopentate (Magnevist,
Schering) induces acute pancreatitis.
Conclusions
What are we to learn from this experience? First, much of
this discussion about the potential harm of intravenous
contrast material used during CECT is currently a moot
point, because CECT is usually not used (or needed) in
making the clinical diagnosis of severe acute pancreatitis in
the first 48–72 h of onset; the clinical scoring systems are
sufficient for the majority of patients with severe acute pan-
creatitis. Treatment in an intensive care unit setting should
begin immediately and be based on the clinical diagnosis
of severe acute pancreatitis, and treatment should not be
withheld despite the lack of an “objective” diagnosis based
on an objective imaging modality. In this setting, CECT is
best reserved for recognition of complications of the nec-
rotizing process that usually begin more than 5 days after
onset of the pancreatitis, i.e., infected necrosis, pancreatic
abscess, extensive peripancreatic fluid collections, or later
pseudocysts. In contrast, in the small subset of patients in
Fig. 3 Post-intravenous con-
trast-enhanced magnetic reso-
nance image (T1) with multiple,
dilated, pancreatic ducts (ar-
rows) in the pancreatic head
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whom the diagnosis is in doubt or in whom an abdominal
catastrophe requiring urgent operation is feared, CECT
should not necessarily be summarily excluded for fear of
exacerbating the pancreatitis. Indeed, the evidence of a
harmful effect of the intravenous contrast agents used dur-
ing CECT is not convincing, especially if the patient is
resuscitated appropriately from a hemodynamic standpoint.
For those institutions with ready access to MRI, this im-
aging modality allows another option with use of intrave-
nous gadopentate, a non-iodinated contrast agent. However,
until MRI becomes more financially appropriate and uni-
versally available, CECTshould remain the “gold standard”
when necessary for the diagnosis of necrotizing pancrea-
titis and, especially, as the primary imaging modality for
identifying and directing interventional and surgical ther-
apy of complications of necrotizing pancreatitis.
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